Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis.
Wolf AS, Ravussin A, König M, Øverås MH, Solum G, Kjønstad IF, Chopra A, Holmøy T, Harbo HF, Syversen SW, Jørgensen KK, Høgestøl EA, Vaage JT, Celius EG, Lund-Johansen F, Munthe LA, Nygaard GO, Mjaaland S. Wolf AS, et al. Among authors: jorgensen kk. JCI Insight. 2023 Jun 22;8(12):e165111. doi: 10.1172/jci.insight.165111. JCI Insight. 2023. PMID: 37159281 Free PMC article.
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).
Syversen SW, Goll GL, Jørgensen KK, Olsen IC, Sandanger Ø, Gehin JE, Warren DJ, Sexton J, Mørk C, Jahnsen J, Kvien TK, Bolstad N, Haavardsholm EA. Syversen SW, et al. Among authors: jorgensen kk. Trials. 2020 Jan 6;21(1):13. doi: 10.1186/s13063-019-3734-4. Trials. 2020. PMID: 31907007 Free PMC article.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T, Ystrøm CM, Torp R, Mielnik P, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. Among authors: jorgensen kk. JAMA. 2021 May 4;325(17):1744-1754. doi: 10.1001/jama.2021.4172. JAMA. 2021. PMID: 33944876 Free PMC article. Clinical Trial.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. Among authors: jorgensen kk. JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316. JAMA. 2021. PMID: 34932077 Free PMC article. Clinical Trial.
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, Jørgensen KK, Jahnsen J, Kro GB, Warren DJ, Vaage EB, Kvien TK, Nissen-Meyer LH, Anderson AM, Grødeland G, Haavardsholm EA, Vaage JT, Mjaaland S, Syversen SW, Lund-Johansen F, Munthe LA, Goll GL. Jyssum I, et al. Among authors: jorgensen kk. Lancet Rheumatol. 2022 Mar;4(3):e177-e187. doi: 10.1016/S2665-9913(21)00394-5. Epub 2021 Dec 23. Lancet Rheumatol. 2022. PMID: 34977602 Free PMC article.
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.
Brun MK, Goll GL, Jørgensen KK, Sexton J, Gehin JE, Sandanger Ø, Olsen IC, Klaasen RA, Warren DJ, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA, Syversen SW. Brun MK, et al. Among authors: jorgensen kk. J Intern Med. 2022 Sep;292(3):477-491. doi: 10.1111/joim.13495. Epub 2022 Apr 26. J Intern Med. 2022. PMID: 35411981 Free PMC article. Clinical Trial.
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy.
Syversen SW, Jyssum I, Tveter AT, Tran TT, Sexton J, Provan SA, Mjaaland S, Warren DJ, Kvien TK, Grødeland G, Nissen-Meyer LSH, Ricanek P, Chopra A, Andersson AM, Kro GB, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Lund-Johansen F, Jørgensen KK, Goll GL. Syversen SW, et al. Among authors: jorgensen kk. Arthritis Rheumatol. 2022 Aug;74(8):1321-1332. doi: 10.1002/art.42153. Epub 2022 Jun 29. Arthritis Rheumatol. 2022. PMID: 35507355 Free PMC article.
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia.
Bjørlykke KH, Jahnsen J, Brynskov J, Molander P, Eberhardson M, Davidsdottir LG, Sipponen T, Hjortswang H, Goll GL, Syversen SW, Langholz E, Jørgensen KK, Steenholdt C. Bjørlykke KH, et al. Among authors: jorgensen kk. Scand J Gastroenterol. 2023 Jan;58(1):25-33. doi: 10.1080/00365521.2022.2108684. Epub 2022 Aug 23. Scand J Gastroenterol. 2023. PMID: 35996928 Free article.
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE, Jyssum I, Tveter AT, Sexton J, Tran TT, Mjaaland S, Kro GB, Kvien TK, Warren DJ, Jahnsen J, Munthe LA, Haavardsholm EA, Vaage JT, Grødeland G, Lund-Johansen F, Jørgensen KK, Syversen SW, Goll GL, Provan SA. Christensen IE, et al. Among authors: jorgensen kk. BMC Med. 2022 Oct 5;20(1):378. doi: 10.1186/s12916-022-02587-8. BMC Med. 2022. PMID: 36199139 Free PMC article.
45 results